ClinicalTrials.gg
CompletedNCT00379795Updated May 11, 2017Results posted

An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

An interventional study of Ranibizumab 0.5 mg in Choroidal Neovascularization, Age-related Macular Degeneration, sponsored by Genentech, Inc.. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-05-11.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
853
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
3rd of 45
853 · median 62
Started
2005
with 3 others
No phase
2 of 45
none open now
Registered
5th of 45
by date
Lead sponsor
2 of 45
Genentech, Inc.

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 3rd largest by enrollment, is one of 4 that started in 2005, is one of 2 with no phase, and was the 5th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort enrolled patients with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). The results of the second cohort are reported separately (NCT01442064). The first cohort of this study enrolled two subsets of patients: ranibizumab experienced and ranibizumab-naive. Patients were enrolled within 14 days of completion of the 24 month treatment phase of the previous study.

03

Conditions studied

  • Choroidal Neovascularization, Age-related Macular Degeneration

Keywords

  • CNV
  • Lucentis
  • AMD
  • Age-related macular degeneration
  • RVO
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Completion of the treatment phase (through Month 24) of a Genentech-sponsored ranibizumab study for AMD (FVF2598g, FVF2587g, or FVF2428g) (Cohort 1)
  • Expectation by the investigator that the subject may potentially benefit from intravitreal anti-vascular endothelial growth factor (VEGF) treatment

Exclusion criteria

Exclusion Criteria:

  • Previous subfoveal focal laser photocoagulation in the study eye
  • Previous pegaptanib sodium injection in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0 of this extension study
  • History of submacular surgery or other surgical intervention for AMD in the study eye
  • History of glaucoma filtering surgery in the study eye
  • History of corneal transplant in the study eye
  • Concurrent use of systemic anti-EGF agents
  • Use of AMD treatments not approved by the FDA
  • Use of intravitreal Avastin(R) (bevacizumab) in the study eye and/or fellow eye
  • CNV in either eye due to other causes than AMD, such as ocular histoplasmosis, trauma, or pathologic myopia for Cohort 1
  • History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 30 mmHg despite treatment with antiglaucoma medication)
  • Pregnancy or lactation
  • Premenopausal women not using adequate
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications
  • Current treatment for active systemic infection
  • Inability to comply with study or follow-up procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
853 participants (actual)

Study arms

  • Experimental
    Ranibizumad 0.5 mg

    Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.

    Drug: Ranibizumab 0.5 mg

Interventions

  • Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Ocular Adverse Events

    Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye). Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.

    Time frame: 36 months

  2. Number of Participants With Non-ocular Adverse Events

    Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.

    Time frame: 36 months

  3. Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24

    Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.

    Time frame: Month 12 and 24

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters

    Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.

    Time frame: Extension study baseline, Months 3, 6, 9, 12, 15, 18, 21 and 24

  2. Change From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters

    Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.

    Time frame: Extension study baseline, Months 12 and 24

07

Results

Posted Jan 13, 2012

Participant flow

This is an open label multicenter extension study for participants who have completed one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823). Cohort 1 includes patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).

Participant flow — Overall Study
MilestoneRanibizumabTreated Initial MonoRanibizumabTreated Initial + PDTRanibizumabTreated Sham XORanibizumab Treated PDT XORanibizumab Untreated Group
Started526741167463
Received ranibizumab in extension study37741113550
Completed502323614
Not completed47651936849
Withdrew: Death318647
Withdrew: Adverse event173314
Withdrew: Lost to follow-up81214
Withdrew: Physician decision250222
Withdrew: Withdrawal by subject941119714
Withdrew: Subject non-compliance72001
Withdrew: Verteporfin photodynamic therapy in eye30010
Withdrew: Subjects condition mandated intervention349757
Withdrew: Sponsor's decision25717544710

Outcome measures

PrimaryNumber of Participants With Ocular Adverse Events

Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye). Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.

Time frame:
36 months
Reported as:
Number · participants
Number of Participants With Ocular Adverse Events
participantsRanibizumab Treated Initial MonoRanibizumab Treated Initial + PDTRanibizumab Treated Sham XORanibizumab Treated PDT XO
Any adverse event in study eye418569659
Serious adverse events in study eye46262
Adverse events led to discontinuation, study eye7232
Endophthalmitis in study eye1000
Intraocular inflammation in study eye, total8241
Serious Intraocular inflammation in study eye1000
Any adverse event in fellow eye304507247
Serious adverse events in fellow eye22463
Adverse events led to discontinuation, fellow eye6743
Endophthalmitis in fellow eye0000
Intraocular inflammation in fellow eye, total5000
Serious intraocular inflammation in fellow eye1000
PrimaryNumber of Participants With Non-ocular Adverse Events

Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.

Time frame:
36 months
Reported as:
Number · participants
Number of Participants With Non-ocular Adverse Events
participantsRanibizumab Treated Initial MonoRanibizumab Treated Initial + PDTRanibizumab Treated Sham XORanibizumab Treated PDT XO
Any non ocular adverse event427619258
Serious non ocular adverse event169213320
Non ocular adverse events led to discontinuation27210
Death31864
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters

Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.

Time frame:
Extension study baseline, Months 3, 6, 9, 12, 15, 18, 21 and 24
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters
lettersRanibizumab Initial GroupRanibizumab Crossover GroupRanibizumab Untreated GroupTotal
Change from Baseline at Month 3 (n=284, 84, 25)-2.9 ± 8.9-2.9 ± 11.00.1 ± 6.6-2.7 ± 9.3
Change from Baseline at Month 6 (n=519, 149, 46)-3.4 ± 8.8-1.6 ± 10.50.3 ± 7.0-2.8 ± 9.1
Change from Baseline at Month 9 (n=490, 149, 38)-4.4 ± 10.8-1.7 ± 11.3-2.2 ± 7.5-3.7 ± 10.8
Change from Baseline at Month 12 (n=481, 142, 38)-5.2 ± 11.1-2.3 ± 11.5-3.2 ± 8.0-4.5 ± 11.1
Change from Baseline at Month 15 (n=447, 138, 31)-5.6 ± 10.8-2.2 ± 12.4-3.0 ± 8.9-4.7 ± 11.2
Change from Baseline at Month 18 (n=420, 135, 28)-6.4 ± 11.9-2.0 ± 12.5-4.4 ± 9.5-5.3 ± 12.1
Change from Baseline at Month 21 (n=405, 129, 28)-7.9 ± 13.0-2.1 ± 13.3-3.5 ± 10.8-6.3 ± 13.2
Change from Baseline at Month 24 (n=388, 127, 27)-8.1 ± 13.0-2.0 ± 13.5-2.9 ± 8.5-6.4 ± 13.2
SecondaryChange From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters

Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.

Time frame:
Extension study baseline, Months 12 and 24
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters
lettersRanibizumab Initial GroupRanibizumab Crossover GroupRanibizumab Untreated GroupTotal
Change from Baseline at Month 12 (n=446,133,35)-5.4 ± 11.8-1.3 ± 11.8-3.2 ± 7.2-4.4 ± 11.7
Change from Baseline at Month 24 (n=352,122,25)-7.5 ± 12.3-0.8 ± 13.0-3.1 ± 8.2-5.7 ± 12.7
PrimaryNumber of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24

Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.

Time frame:
Month 12 and 24
Reported as:
Number · participants
Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24
participantsRanibizumab Treated Initial MonoRanibizumab Treated Initial + PDTRanibizumab Treated Sham XORanibizumab Treated PDT XO
Month 12 (n=393,55,72,50)10010
Month 24 (n=316,45,78,42)9010

Adverse events

Collected over The summary includes adverse events that occurred from enrollment in this extension study through 36 months (+/- 7 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab Treated Initial Mono—213/526 (40.5%)491/526 (93.3%)
Ranibizumab Treated Initial + PDT—26/74 (35.1%)70/74 (94.6%)
Ranibizumab Treated Sham XO—43/116 (37.1%)110/116 (94.8%)
Ranibizumab Treated PDT XO—24/74 (32.4%)71/74 (95.9%)
Most frequent serious events
Showing 10 of 207
Most frequent serious events
EventRanibizumab Treated Initial MonoRanibizumab Treated Initial + PDTRanibizumab Treated Sham XORanibizumab Treated PDT XO
MACULAR DEGENERATIONEye disorders21/5262/745/1161/74
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders8/5262/741/1163/74
PNEUMONIAInfections and infestations13/5261/744/1160/74
ATRIAL FIBRILLATIONCardiac disorders8/5260/744/1160/74
CHOROIDAL NEOVASCULARISATIONEye disorders7/5262/742/1162/74
LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/5262/741/1160/74
COLON CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5260/741/1162/74
DEHYDRATIONMetabolism and nutrition disorders1/5260/743/1161/74
SPINAL COLUMN STENOSISMusculoskeletal and connective tissue disorders0/5260/743/1161/74
VISUAL ACUITY REDUCEDEye disorders11/5261/740/1160/74
Most frequent other events
Showing 10 of 46
Most frequent other events
EventRanibizumab Treated Initial MonoRanibizumab Treated Initial + PDTRanibizumab Treated Sham XORanibizumab Treated PDT XO
MACULAR DEGENERATIONEye disorders236/52618/7453/11622/74
RETINAL HAEMORRHAGEEye disorders197/52621/7447/11631/74
CONJUNCTIVAL HAEMORRHAGEEye disorders124/52620/7433/11617/74
CHOROIDAL NEOVASCULARISATIONEye disorders63/52615/7416/11610/74
CATARACTEye disorders61/52612/748/11611/74
INTRAOCULAR PRESSURE INCREASEDInvestigations73/5266/7415/1163/74
ARTHRALGIAMusculoskeletal and connective tissue disorders31/52610/746/1165/74
MACULAR OEDEMAEye disorders70/5266/7415/1168/74
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders31/5265/745/1169/74
NASOPHARYNGITISInfections and infestations48/5269/749/1167/74

Baseline characteristics

Age, Customized
Age, Customized(participants)RanibizumabTreated Initial MonoRanibizumabTreated Initial + PDTRanibizumabTreated Sham XORanibizumab Treated PDT XORanibizumab Untreated GroupTotal
50 to < 6529558451
65 to < 7511719272110194
75 to < 8527742613529444
>= 851038231020164
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabTreated Initial MonoRanibizumabTreated Initial + PDTRanibizumabTreated Sham XORanibizumab Treated PDT XORanibizumab Untreated GroupTotal
Female30442764136499
Male22232403327354
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2006
First posted
Sep 22, 2006
Start
Apr 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Jan 13, 2012
Last update
May 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00379795
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2006
Start date
Apr 2005
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Jan 13, 2012
Last update
May 11, 2017

Study contacts

Lisa Tuomi, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion